Proactive Investors - Run By Investors For Investors

VBI Vaccines shares pop after Oppenheimer analyst kicks off coverage with Outperform rating

Oppenheimer's Leland Gershell thinks positive news flow from any of VBIV's three vaccine programs could trigger share price appreciation
medical syringe
The company focuses on developing vaccines to address infectious disease

Shares of VBI Vaccines Inc (NASDAQ:VBIV) soared Wednesday after an Oppenheimer analyst initiated coverage of the commercial-stage, bio-pharmaceutical group with an Outperform rating and a $9 price target.

A specialist in vaccines, VBI is moving forward with three drug candidates. The first is a hepatitis B vaccine, Sci-B-Vac, which is approved for use in Israel and 10 other countries, but is currently only in a Phase 3 study in the US, Europe and Canada. Its other two drugs include a vaccine for the prevention of cytomegalovirus (CMV), a common virus that infects people regardless of age, as well as a therapeutic glioblastoma vaccine candidate to address malignant tumors.

READ: Baird analysts stay Neutral on biotech sector as 2019 gets underway

“We see pivotal-stage hepB vaccine Sci-B-Vac as low risk, and its ability to protect less tractable populations should make it a niche competitor,"  wrote Oppenheimer’s Leland Gershell in a note published on analystratings.com. "The company’s eVLP technology is being leveraged for CMV (to enter Phase 2 in late 2019) as well as glioblastoma (in Phase 1/2).”

Gershell concluded that positive news flow from any of VBIV’s programs could trigger share appreciation.

Applauding Gershell’s bullish stance, investors sent VBI Vaccines shares up by 7.9% to US$1.91 in afternoon trading on Wednesday.

Headquartered in Cambridge, Massachusetts, VBI is focused on developing vaccines to address infectious disease and bolster immune-oncology programs. VBI also has research operations in Ottawa, as well as research and manufacturing facilities in Rehovot, Israel.

Contact Ellen Kelleher at [email protected]

View full VBIV profile View Profile

VBI Vaccines Inc Timeline

Related Articles

young girl with allergy
March 22 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use